Gregory T. Everson

Gregory T. Everson's AcademicInfluence.com Rankings

Gregory T. Everson

Philosophy

#7907

World Rank

#11188

Historical Rank

Logic

#4942

World Rank

#6282

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Gregory T. Everson's Degrees

Doctorate Medicine University of Colorado

Why Is Gregory T. Everson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gregory T. Everson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. (2014) (1202)
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (2013) (1122)
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. (2009) (905)
Response-guided telaprevir combination treatment for hepatitis C virus infection. (2011) (799)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (2015) (761)
Preliminary study of two antiviral agents for hepatitis C genotype 1. (2012) (634)
Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure (2004) (608)
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. (2004) (501)
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. (2009) (484)
Adult-to-adult transplantation of the right hepatic lobe from a living donor. (2002) (440)
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. (2010) (389)
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy (2005) (382)
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. (2008) (381)
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort (2005) (354)
Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C (2001) (343)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (2014) (342)
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. (2015) (336)
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. (2005) (335)
Adult living donor liver transplantation using a right hepatic lobe. (1998) (311)
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. (1998) (297)
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. (2014) (268)
Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease (1990) (261)
A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction (1980) (241)
Right hepatic lobe donation for living donor liver transplantation: Impact on donor quality of life (2001) (233)
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. (2007) (219)
Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. (1991) (219)
Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. (2014) (196)
Polycystic disease of the liver (2004) (194)
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. (2011) (188)
Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. (1998) (187)
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. (1997) (181)
Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. (1995) (175)
Gallbladder function in the human female: Effect of the ovulatory cycle, pregnancy, and contraceptive steroids (1982) (175)
Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease (1997) (173)
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial (2006) (172)
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. (2004) (172)
Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. (1981) (169)
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. (2012) (168)
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (2011) (163)
Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. (2004) (159)
Adult‐to‐adult living donor liver transplantation using right‐lobe grafts: Results and lessons learned from a single‐center experience (2001) (150)
Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial (2007) (148)
Effects of psyllium hydrophilic mucilloid on LDL-cholesterol and bile acid synthesis in hypercholesterolemic men. (1992) (144)
Role of Oxidant Stress in the Permeability Transition Induced in Rat Hepatic Mitochondria by Hydrophobic Bile Acids (2001) (142)
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. (2014) (141)
Review and management of drug interactions with boceprevir and telaprevir (2012) (138)
A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. (1980) (132)
Living donor liver transplantation: Summary of a conference at The National Institutes of Health (2002) (131)
Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss (1997) (131)
Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial (1996) (130)
Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. (1997) (128)
Impact of immunosuppressive therapy on recurrence of hepatitis C (2002) (126)
Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort † (2012) (125)
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. (2015) (125)
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation (2013) (123)
Extrarenal manifestations of autosomal dominant polycystic kidney disease. (1991) (121)
Drug–drug interactions during antiviral therapy for chronic hepatitis C (2013) (120)
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation (2007) (118)
Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. (1991) (117)
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era (2011) (116)
Gastrointestinal transit time in human pregnancy: prolongation in the second and third trimesters followed by postpartum normalization. (1985) (116)
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications (2003) (115)
Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation (2003) (112)
Polycystic liver disease: Quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts (1988) (108)
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension (2017) (108)
Functional similarities of hepatic cystic and biliary epithelium: Studies of fluid constituents and in vivo secretion in response to secretin (1990) (108)
Benign focal lesions of the liver. (2001) (107)
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease (2007) (107)
Liver transplantation using sirolimus and minimal corticosteroids (3‐day taper) (2001) (105)
Gastrointestinal motility in pregnancy. (1992) (105)
Model for End‐Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients (2003) (104)
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection (2015) (103)
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. (2006) (103)
Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD (2004) (102)
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. (2001) (101)
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. (2010) (91)
Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. (2000) (86)
Hepatic Artery Chemoembolization for Hepatocellular Carcinoma in Patients Listed for Liver Transplantation (2004) (83)
Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus (2001) (83)
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. (2014) (79)
66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS (2008) (79)
Liver transplantation for alcoholic liver disease: Bias, beliefs, 6‐month rule, and relapse—but where are the data? (2000) (79)
Prevention of Post‐transplant Cardiovascular Disease – Report and Recommendations of an Ad Hoc Group 1 (2002) (77)
Treatment of patients with hepatitis C virus on the waiting list (2003) (77)
Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. (1999) (75)
Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial (2006) (75)
1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS (2012) (74)
Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation. (1997) (74)
O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY (2014) (73)
Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial (2009) (71)
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection (2003) (71)
HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. (1986) (71)
Gallbladder function in gallstone disease. (1991) (69)
Liver regeneration after living donor transplantation: Adult‐to‐adult living donor liver transplantation cohort study (2015) (69)
Biliary lipids, bile acids, and gallbladder function in the human female: effects of contraceptive steroids. (1982) (69)
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation (2001) (69)
Increased secondary bile acids in a choledochal cyst. Possible role in biliary metaplasia and carcinoma. (1990) (67)
Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry. (1987) (67)
1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS (2011) (66)
O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A) (2015) (65)
Endoscopic Gallbladder Stent Placement for Treatment of Symptomatic Cholelithiasis in Patients with End-Stage Liver Disease (2006) (65)
Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics (1999) (65)
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus–related cirrhosis (2003) (62)
Pregnancy and Gallstones (1993) (60)
3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY (2013) (60)
1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) (2013) (60)
Early steroid withdrawal in liver transplantation is safe and beneficial. (1999) (59)
Gallbladder function in the human female: effect of the ovulatory cycle, pregnancy, and contraceptive steroids. (1982) (59)
Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. (1999) (59)
Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis (HALT‐C) trial (2009) (58)
A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy (2006) (57)
4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C (2008) (57)
Hepatofugal portal flow in cirrhosis: Observations on hepatic hemodynamics and the nature of the arterioportal communications (1988) (56)
Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. (2011) (55)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. (2016) (54)
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis trial (2012) (54)
Contraceptive steroids increase cholesterol in bile: mechanisms of action. (1987) (53)
Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients (2002) (53)
Portal vein thrombolysis and closure of competitive shunts following liver transplantation. (1994) (52)
All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database (2017) (50)
Hepatic cysts in autosomal dominant polycystic kidney disease. (1990) (48)
Bile acid synthesis in cultured human hepatoblastoma cells. (1991) (48)
Substrate stimulation of 7 alpha-hydroxylase, an enzyme located in the cholesterol-poor endoplasmic reticulum. (1990) (48)
Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. (1995) (48)
1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome. (1997) (47)
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. (2007) (47)
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. (2015) (46)
Conduction defects and mitral annulus calcification. (1980) (45)
HCV NS5B polymerase inhibitors. (2009) (45)
Outcomes of Donor Evaluations for Adult‐to‐Adult Right Hepatic Lobe Living Donor Liver Transplantation (2006) (45)
Laparoscopic palliation of polycystic liver disease (2004) (45)
Gallbladder and small intestinal regulation of biliary lipid secretion during intraduodenal infusion of standard stimuli. (1983) (44)
O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION (2014) (44)
Coordination of gastric and gallbladder emptying after ingestion of a regular meal (1983) (44)
Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions (2017) (43)
Endoscopic stenting of the gallbladder for symptomatic gallbladder disease in patients with end-stage liver disease awaiting orthotopic liver transplantation. (1999) (43)
Total parenteral nutrition and cholestasis. (1999) (42)
Hepatic cysts in autosomal dominant polycystic kidney disease. (1993) (41)
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. (2010) (41)
Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation (2000) (40)
Treatment of chronic hepatitis C in patients with decompensated cirrhosis. (2004) (40)
Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantion (2003) (39)
MELD: the answer or just more questions? (2003) (39)
O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience (2015) (38)
Gallbladder function is altered in sickle hemoglobinopathy. (1989) (37)
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. (2009) (37)
The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria. (1998) (33)
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4 (2015) (33)
23 A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP (2013) (32)
1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS (2013) (32)
Increasing incidence and pretransplantation screening of hepatocellular carcinoma (2000) (31)
Controversies in the management of hepatitis C virus infection after liver transplantation (2003) (31)
Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration (1999) (31)
Should we treat patients with chronic hepatitis C on the waiting list? (2005) (31)
LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension (2015) (31)
Management of cirrhosis due to chronic hepatitis C. (2005) (31)
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. (2008) (30)
993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (30)
Noninvasive assessment of liver function (2015) (30)
Coordination of gastric and gallbladder emptying after ingestion of a regular meal. (1983) (29)
Characteristics and regulation of bile salt synthesis and secretion by human hepatoma HepG2 cells (1994) (29)
[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C (2007) (28)
Contraceptive steroids alter the steady-state kinetics of bile acids. (1988) (28)
Management of the transplant recipient with chronic hepatitis C. (2013) (28)
Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. (1997) (28)
Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study (2016) (28)
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. (2006) (27)
A method for the accurate measurement of isotope ratios of chenodeoxycholic and cholic acids in serum. (1982) (27)
1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS (2011) (27)
10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy (2013) (26)
Maintenance interferon for chronic hepatitis C: More issues than answers? (2000) (26)
226 Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the Solar 1 and Solar 2 Trials (2015) (26)
1207 TRIPLE THERAPY WITH DACLATASVIR (DCV; BMS-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL (2012) (26)
Interpretation of positive transcription‐mediated amplification test results from polymerase chain reaction–negative samples obtained after treatment of chronic hepatitis C (2008) (25)
Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection (2015) (25)
Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C. (2004) (25)
Rapid, accurate, and sensitive fatty acid ethyl ester determination by gas chromatography-mass spectrometry. (2006) (24)
High relapse rate seen at week 72 for patients treated with R1626 combination therapy (2008) (24)
Management of polycystic liver disease (2005) (23)
The Effects of Desflurane and Propofol on Portosystemic Pressure in Patients with Portal Hypertension (2003) (23)
Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss (2001) (22)
Chronic Albumin Infusions to Achieve Diuresis in Patients with Ascites Who Are Not Candidates for Transjugular Intrahepatic Portosystemic Shunt (TIPS) (2005) (22)
Advances in management of polycystic liver disease (2008) (22)
Cholecystokinin-Cholescintigraphy in Adults: Consensus Recommendations of an Interdisciplinary Panel (2012) (21)
Atrial septal perforation from TIPS stent migration. (2004) (21)
Everolimus and mTOR inhibitors in liver transplantation: Opening the “box” (2006) (21)
Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS (2014) (21)
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. (2013) (20)
1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS (2012) (20)
Sofosbuvir and velpatasvir for the treatment of hepatitis C (2017) (20)
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT‐C trial (2009) (20)
Percutaneous mesenteric venous thrombectomy and thrombolysis: successful treatment followed by liver transplantation. (1998) (20)
Plasma glucagon concentration in cirrhosis is related to liver function but not to portal-systemic shunting, systemic vascular resistance, or urinary sodium excretion. (1991) (20)
Transference of peanut allergy through liver transplantation (2001) (20)
Radiation-induced intestinal pseudoobstruction. (1986) (19)
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. (2004) (19)
Changes in liver and spleen volumes after living liver donation: A report from the adult‐to‐adult living donor liver transplantation cohort study (A2ALL) (2015) (19)
Portal‐systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt (2007) (18)
Renal sodium retention complicating alcoholic liver disease: Relation to portosystemic shunting and liver function (1990) (18)
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study (2019) (18)
P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials (2015) (18)
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study (2015) (17)
Treatment of chronic hepatitis C with interferon alfa‐n3: A multicenter, randomized, open‐label trial (1997) (17)
Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS) (1995) (17)
Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. (1996) (17)
Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation (2020) (16)
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C (2012) (16)
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study (2014) (16)
Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. (2019) (16)
HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension (2016) (16)
A hepatologist's perspective on the management of coagulation disorders before liver transplantation. (1997) (16)
1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS (2012) (16)
Benign recurrent intrahepatic cholestasis: treatment with S-adenosylmethionine. (1989) (15)
2006 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS (2010) (15)
Effects of specific inhibition of sterol biosynthesis on the uptake and utilization of low density lipoprotein cholesterol by HepG2 cells. (1991) (15)
1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL (2010) (15)
Modulation of Interferon-Specific Gene Expression by Albumin-Interferon-α in Interferon-α-Experienced Patients with Chronic Hepatitis C (2006) (15)
Antiviral therapy for hepatitis C in the setting of liver transplantation (2006) (14)
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia (2015) (14)
P.2.090 The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function (1997) (14)
Treatment of hepatitis C in patients who have decompensated cirrhosis. (2005) (13)
Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis (2005) (13)
Bile acid metabolism and its role in human cholesterol balance. (1992) (12)
De Novo Hepatocellular Carcinomain a Patient with Chronic Hepatitis C 5 Years After Sustained Virologic Response to Interferon/Ribavirin Therapy (2006) (11)
Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. (2006) (11)
On-Treatment HCV RNA in Patients with Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial (2016) (10)
The variable presentations and broadening geographic distribution of hepatic fascioliasis. (2012) (10)
Hepatocyte transplantation (HT) in-patients with liver cirrhosis (1998) (9)
Design of the halt-C trial (Hepatitis C antiviral long-term treatment to prevent Cirrhosis) (2000) (9)
Simultaneous Determination of Caffeine and Antipyrine in Plasma and Saliva using High-Performance Liquid Chromatography (1990) (9)
Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation. (2020) (9)
Hepatocyte-hepatoma cell hybrids. Characterization and demonstration of bile acid synthesis. (1986) (9)
Polycystic liver disease. (2008) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION (2013) (8)
223 Prove1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Hepatitis C (2008) (8)
763 All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and Bms-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection (2014) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Liver problems in pregnancy: distinguishing normal from abnormal hepatic changes. (1998) (7)
Somatostatin, estrogen, and polycystic liver disease. (2013) (7)
604 Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir Treatment of Patients With HCV Genotype 1-Infection Who Failed a Prior Course of DAA Therapy: The QUARTZ-I Study (2016) (7)
Viral hepatitis: Drug–drug interactions in HCV treatment — the good, the bad and the ugly (2016) (7)
All-oral Dual Therapy with Daclatasvir and Asunaprevir in Patients with HCV Genotype 1B Infection (2014) (7)
Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group. (1999) (6)
Assessing hepatic impairment in Fontan-associated liver disease using the HepQuant SHUNT test. (2019) (6)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease (2009) (6)
Predicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT test (2021) (6)
Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation? (2018) (6)
The Within-Individual Reproducibility of the Disease Severity Index from the HepQuant SHUNT® Test of Liver Function and Physiology. (2021) (6)
P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation (2015) (6)
Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
Controlling for serum albumin level improves the correlation between serum fatty acid ethyl esters and blood ethanol level. (2007) (6)
A COMPARISON OF CHARGES FOR ORGAN ACQUISITION: ADULT CADAVERIC VS. ADULT LIVING DONOR LIVER TRANSPLANTATION.: Abstract# 238 Poster Board #‐Session: P85‐I (2000) (6)
Transference of peanut allergy through liver transplantation. (2001) (6)
Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo- b -lactamase-producing Klebsiella oxytoca (2014) (6)
627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES (2009) (5)
818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR (2013) (5)
Liver transplantation: current status and unresolved controversies. (1997) (5)
Hepatocellular carcinoma extension into the right atrium (2003) (5)
456 Safety, pharmacokinetics and pharmacodynamic results of higher doses of albuferon in a phase single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C (2004) (5)
609 A Disease Severity Index Based on Dual Cholate Clearances and Shunt Outperforms Biopsy At Predicting Clinical Outcomes in Chronic Hepatitis C (2013) (4)
313 A 1/2phase study to evaluate the pharmacokinetics, safety, tolerability, immunogenicity, and pharmacodynamics of albuferon™ in the treatment experienced subjects with chronic hepatitis C (2003) (4)
HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease. (2021) (4)
Trial of S-adenosylmethionine in patients in two families with cholestatic syndromes. (1991) (4)
Living with Hepatitis C: A Survivor's Guide (1998) (4)
Waiting for "The Liver" - No Longer? (2016) (4)
Lamivudine treatment for decompensated cirrhosis due to hepatitis B: A multicenter longitudinal study (2000) (4)
COSTS OF CYCLOSPORINE (NEORAL®) AND TACROLIMUS (PROGRAF®) IN THE FIRST YEAR AFTER LIVER TRANSPLANTATION (OLT). (1998) (4)
HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape (2015) (4)
Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients (2011) (3)
Corticosteroid withdrawal in solid organ transplantation (1998) (3)
821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results (2014) (3)
309 Quantitative tests (QLFTS) detect impaired hepatic function in a high proportion of chronic hepatitis C patients with fibrosis or compensated cirrhosis and may predict risk of cirrhosis, splenomegally, and varices (2003) (3)
277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS (2010) (3)
1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN (2010) (3)
USE OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT AS A BRIDGE TO TRANSPLANTATION IN BUDDCHIARI SYNDROME. (1998) (3)
P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial (2015) (3)
P-2-18 Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment (1996) (3)
ADULT DONORS OF RIGHT HEPATIC LOBES FOR LIVINGDONOR LIVER TRANSPLANTATION: RESULTS OF FIRST 16 PATIENTS.: Abstract# 237 Poster Board #‐Session: P84‐I (2000) (3)
Original contributionOrlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss (2001) (3)
Deterioration of hepatic function after locoregional therapy (LRT) for hepatocellular carcinoma (HCC) measured by hepatic cholate clearance: A pilot study. (2018) (3)
Immunosuppression in liver transplantation. (2003) (3)
Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis (2016) (3)
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis (2017) (3)
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy (2019) (3)
Title Quantitative Liver Function Tests Improve the Prediction of Clinical Outcomes in Chronic Hepatitis C : Results from the HALT-C Trial Permalink (2012) (2)
Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. (2017) (2)
Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation. (2015) (2)
HALT‐C trial (2002) (2)
715 NON-INVASIVE CHOLATE TESTING PREDICTS RESPONSE TO PEGINTERFERON/RIBAVIRIN AND MEASURES FUNCTIONAL IMPROVEMENT AFTER SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (2013) (2)
LBP-18-Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH (2019) (2)
Conduction defects andmitral annulus calcification (1980) (2)
Is early steroid withdrawal after liver transplantation feasible with tacrolimus monotherapy? (2008) (2)
Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant. (2015) (2)
Liver problems in pregnancy: part 2--managing pre-existing and pregnancy-induced liver disease. (1998) (2)
Treatment of Lamivudine-resistant chronic hepatitis B with tenofovir (2003) (2)
Task force on training in hepatology (1996) (1)
PRO view: treat to prevent recurrence of HCV (2015) (1)
Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. (2017) (1)
Sa1462: THE HEPQUANT SHUNT DISEASE SEVERITY INDEX (HEPQUANT DSI™) CAN AID THE DECISION TO AVOID ENDOSCOPIC SCREENING OR SURVEILLANCE FOR VARICES NEEDING TREATMENT (2022) (1)
Quantitative Liver Function Tests Improve the Prediction of Clinical Outcomes in Chronic Hepatitis C: Results from the HALT-C Trial (2012) (1)
SUCCESSFUL OUTCOME AFTER LIVER TRANSPLANTATION OF PATIENTS WITH“HIGH-RISK” PRETRANSPLANT PSYCHOSOCIAL EVALUATION. (1998) (1)
On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies (2016) (1)
476 PREDICTING DECOMPENSATION, DEATH, OR LIVER TRANSPLANTATION IN CIRRHOSIS BY USING A NON-INVASIVE LIVER FUNCTION TEST (HEPQUANT SHUNT®) (2020) (1)
375 Non-Invasive Measurement of the Portal Circulation Using Cholates Quantifies Disease Severity in Primary Sclerosing Cholangitis (2012) (1)
Outcome after transjugular intrahepatic portal-systemic shunt for refractory ascites in patients with advanced cirrhosis (1995) (1)
Deterioration in liver function after liver‐directed therapy for hepatocellular carcinoma measured by cholate clearance (2020) (1)
Advances and controversies in liver transplantation: Hepatocellular cancer (part I), viral hepatitis (part II), and living donor liver transplantation in adults (part III) (2000) (1)
THE EVALUATION OF ONE‐HUNDRED POTENTIAL RECIPIENTS FOR LIVING DONOR LIVER TRANSPLANTATION.: Abstract# 686 (2000) (1)
Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
Liver Transplantation: Indications, Contraindications and Results (2008) (1)
468 UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS (2011) (1)
410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS (2011) (1)
Utility of transjugular liver biopsy using liver access biopsy automated needle (1998) (0)
Chapter 70 – Fibrocystic Diseases of the Liver (2006) (0)
Upper and Lower GI Bleeding in the ICU (2009) (0)
150 Tacrolimus level/dose ratio is significantly higher in hepatitis C liver transplant recipients: impact on cost (2003) (0)
Quantitative cholescintigraphy. (1981) (0)
Bile acid kinetics in pregnancy and in women receiving contraceptive steroids (CS). (1981) (0)
Differential response to treatment with consensus interferon (CIFN) and IFN alpha-2b in chronic HCV patients infected with different (1996) (0)
Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholes-terolemia without causing graft loss (1997) (0)
A multi-compartmental model of the HepQuant SHUNT test can quantify anatomic shunting and stratify risk for varices: combined results from the HALT-C and SHUNT-V studies (2022) (0)
Quality of life after liver transplantation in patients with hepatitis C (1998) (0)
QUALITY OF LIFE (QOL) AFTER LIVER TRANSPLANTATION: EXTERNAL VALIDATION OF THE NIDDK QOL INSTRUMENT. (1999) (0)
6 Effect of female sex hormones on bi Ie acids (1985) (0)
Natural History of Hepatitis C (2002) (0)
HepG2 HUMAN HEPATOBLASTOMA CELL LINE EXHIBITING DEFECTS IN BILE ACID SYNTHESIS AND (1986) (0)
Abstract 15268: Development of a Reliable Means of Assessment of Liver Function After the Fontan Operation: Dual Cholate Clearance Assay (2020) (0)
Hepatitis C virus: Antiviral therapy in wait‐listed patients (2013) (0)
Tu1290: THE HEPQUANT'S DISEASE SEVERITY INDEX (HEPQUANT DSI™) OUTPERFORMS CHILD-PUGH (CP) CLASSIFICATION IN QUANTIFYING HEPATIC IMPAIRMENT FOR PREDICTION OF DRUG PHARMACOKINETICS (PK) IN CHRONIC LIVER DISEASE (2022) (0)
INCREASED INCIDENCE OF HCV-RELATED HEPATOCELLULAR (HCC) FROM 1988 TO 1997 IN THE STATE OF COLORADO: IMPLICATIONS FOR LIVER TRANSPLANTATION (LTx) (1999) (0)
PGI8 A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANT PATIENTS:A UNIVERSITY HOSPITAL PERSPECTIVE (2004) (0)
The use of mycophenolate mofetil as a Cyclosporine sparing agent in liver transplant recipients with progressive renal insufficiency (1999) (0)
West Nile Virus Seroprevalence and Incidence of Symptomatic Infection in a Cohort of Colorado Transplant Recipients, 2004–2005 (2007) (0)
HCV in Patients with Advanced Disease: Do you Treat them and do you have any Caveats? (2010) (0)
Chapter 28 – Biliary Disease, Gallstones and Cystic Disease (2006) (0)
Effect of female sex hormones on bile acids (1985) (0)
Treating recurrent hepatitis C with triple therapy (2013) (0)
815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAÏVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTS (2013) (0)
CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C (2007) (0)
Virologic Response Rates to Fixed-Dose Combination Ledipasvir/Sofosbuvir for 8 or 12 Weeks With Baseline Viral Load: 2061 (2015) (0)
Tu1021 Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation (2015) (0)
Faculty Opinions recommendation of Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. (2009) (0)
265 FATTY ACID ETHYL ESTERS AND BLOOD ALCOHOL LEVEL: INTOXICATION, TOLERANCE, AND INFLUENCE OF GENDER AND AGE (2005) (0)
Ob-Gyn interactive case challenge--liver disease in the third trimester of pregnancy. (1998) (0)
Diagnostic Items for Renal and Hepatic Cyst Infection – A Delphi Survey (2015) (0)
P0814 : Hepatic improvement in response to ledipasvir/sofosbuvir/ribavirin as measured by the hepquant® (HQ)-shunt test in liver transplant (LT) recipients with allograft fibrosis or cirrhosis and non-LT patients with decompensated cirrhosis (2015) (0)
LIVER TRANSPLANT‐RELATED BILIARY COMPLICATIONS IN THE POST T‐TUBE ERA.: Abstract# 792 Poster Board #‐Session: P49‐III (2000) (0)
765 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES (2010) (0)
What you should know about living donor liver transplantation (2004) (0)
Sodium retention does not occur at a critical threshold of liver function in alcoholic cirrhosis. (1994) (0)
Editorial: stratifying risk of adverse outcomes in cirrhosis—the Hepquant SHUNT test. Authors' reply (2021) (0)
Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies (2016) (0)
Chapter 67 – Fibrocystic Diseases of the Liver (2012) (0)
The Future is Now: Challenges and Opportunities in Infectious Disease (2010) (0)
FUJISAWA HEALTHCARE, INC. PRESENTS IMAGES IN LIVER TRANSPLANTATION Hepatocellular Carcinoma Extension Into the Right Atrium (2003) (0)
Antiviral therapy in the liver transplant candidate and recipient (2005) (0)
262 MEASUREMENT OF DEUTERATED ISOTOPES OF CAFFEINE USING CAPILLARY GAS CHROMATOGRAPHY-MASS SPECTROMETRY. (2006) (0)
Compartmental Model Describing the Physiological Basis for the HepQuant SHUNT Test. (2022) (0)
My Mom Has Hepatitis C (2000) (0)
Treatment of Hepatitis C After Liver Transplantation (2014) (0)
Sa1021 The use of Noninvasive Indices of Hepatic Fibrosis to Detect Clinically Significant Portal Hypertension (2012) (0)
Obituary: The Impact of Thomas Earl Starzl, MD, PhD. (2017) (0)
LAMIVUDINE TREATMENT OF HEPATITIS B FOLLOWING LIVER TRANSPLANTATION: A MULTI‐CENTER U.S. STUDY.: Abstract# 598 (2000) (0)
Difficult-to-treat patients with chronic hepatitis C (Part One) (2005) (0)
LONG-TERM MANAGEMENT AFTER LIVER TRANSPLANTATION: PRIMARY CARE PHYSICIAN VS. HEPATOLOGIST? (2006) (0)
COMPONENTS OF CARE RESPONSIBLE FOR THE RISING COSTS INCURRED DURING THE PRE-TRANSPLANT PERIOD IN LIVER TRANSPLANT RECIPIENTS. (1998) (0)
EFFECT OF HEPATITIS C ON SURVIVAL IN ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS UNDERGOING RAPID STEROID WITHDRAWAL (1999) (0)
Scientific Program (2003) (0)
25.1. Surgical Techniques (2008) (0)
64 – Fibrocystic Diseases of the Liver (2018) (0)
Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study: 364 (2013) (0)
Studies on biosynthetic pathways to bile acids in human liver cells (2007) (0)
The HepQuant-STAT Liver Function Test Predicts the Risk for Future Clinical Outcomes in Chronic Hepatitis C Virus Infection and Could Help Prioritize Patients for Antiviral Treatment (2015) (0)
Medical Treatments in Patients with Primary Sclerosing Cholangitis Differ between Europe and North America (2016) (0)
Treatment of Chronic Hepatitis C in the Age of Direct-Acting Antivirals with Emphasis on First Generation Inhibitors of HCV NS3/4A Protease (2011) (0)
764 Preliminary analysis: graft loss from recurrent hepatitis C is not increased in patients receiving sirolimus as primary immunosuppression (2003) (0)
Gender Differences among Hepatitis C-Infected Liver Transplant Recipients on Protease Inhibitor Triple Therapy. (2013) (0)
PSC Partners Seeking a Cure Newsletter (2006) (0)
Measurement of Deuterated Isotopes of Caffeine Using Capillary Gas Chromatography-Mass Spectrometry (2006) (0)
Treating HCV Prior to Liver Transplantation (2012) (0)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C (2010) (0)
Reply: (2007) (0)
Does Pre-Transplant ERCP with Balloon Dilation Alone (ERCPBD), Stenting (ERCPST), Or PTC with Drainage Tubes (PTCDT) Decrease MELD Score Or Delay Liver Transplantation in Patients with Primary Sclerosing Cholangitis (PSC)? (2007) (0)
1112 Frequency of Familial Primary Sclerosing Cholangitis (PSC) and Inflammatory Bowel Disease: Results From the PSC Partners Patient Registry (2016) (0)
IS ROUTINE INTENSIVE CARE UNIT (ICU) ADMISSION NECESSARY AFTER ORTHOTOPIC LIVER TRANSPLANTATION (1999) (0)
Mortality increases with Upper Gastrointestinal Bleeding , Lower Gastrointestinal Bleeding , and Hepatic Failure (2003) (0)
SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gregory T. Everson?

Gregory T. Everson is affiliated with the following schools: